Jane Street’s Franklin Genomic Advancements ETF HELX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-8,049
Closed -$217K 10134
2025
Q1
$217K Sell
8,049
-32,981
-80% -$970K ﹤0.01% 8325
2024
Q4
$1.18M Buy
+41,030
New +$1.26M ﹤0.01% 5053
2024
Q2
Sell
-13,886
Closed -$455K 9711
2024
Q1
$455K Sell
13,886
-11,923
-46% -$373K ﹤0.01% 6832
2023
Q4
$786K Buy
25,809
+12,821
+99% +$356K ﹤0.01% 6002
2023
Q3
$368K Buy
12,988
+274
+2% +$8.26K ﹤0.01% 6738
2023
Q2
$384K Buy
12,714
+3,158
+33% +$95.6K ﹤0.01% 6720
2023
Q1
$290K Sell
9,556
-4,924
-34% -$151K ﹤0.01% 7253
2022
Q4
$436K Sell
14,480
-17
-0.1% -$522 ﹤0.01% 6373
2022
Q3
$430K Buy
14,497
+141
+1% +$4.68K ﹤0.01% 6959
2022
Q2
$460K Buy
14,356
+7,462
+108% +$246K ﹤0.01% 6894
2022
Q1
$255K Sell
6,894
-107,429
-94% -$4.09M ﹤0.01% 8649
2021
Q4
$5.54M Buy
+114,323
New +$5.7M ﹤0.01% 2698
2021
Q3
Sell
-36,210
Closed -$1.88M 10241
2021
Q2
$1.88M Sell
36,210
-5,568
-13% -$249K ﹤0.01% 4445
2021
Q1
$1.81M Buy
41,778
+15,833
+61% +$741K ﹤0.01% 4199
2020
Q4
$1.15M Buy
25,945
+18,426
+245% +$734K ﹤0.01% 4416
2020
Q3
$264K Buy
+7,519
New +$256K ﹤0.01% 6065

Other funds holding HELX

Jane Street's HELX Position: Q2 2025 in Review

Jane Street sold out of Franklin Genomic Advancements ETF (HELX) in Q2 2025, closing a stake of 8,049 shares — an estimated $217K sold.

Jane Street first reported a position in HELX in Q3 2020 and held it in 16 quarters. The position peaked at $5.54M in Q4 2021. 8 funds tracked by Wall St. Rank hold HELX as of Q2 2025.

  • Jane Street reported no remaining Franklin Genomic Advancements ETF position as of Q2 2025 after selling out during the quarter.
  • Jane Street sold 8,049 Franklin Genomic Advancements ETF shares in Q2 2025, an estimated $217K.
  • Jane Street first reported a position in Franklin Genomic Advancements ETF in Q3 2020 and held it in 16 quarters.
  • Jane Street's Franklin Genomic Advancements ETF position peaked at $5.54M in Q4 2021.
  • 8 funds tracked by Wall St. Rank held Franklin Genomic Advancements ETF as of Q2 2025.

Based on Jane Street's 13F filing for Q2 2025, filed 14 Aug 2025.